tbuckley/cabot-search huggingface dataset:
Abstract 2771: Development of a non-thermal plasma model for neuroblastoma treatment.
Authors: Priya Srinivasan, Jason A. Snyder, Alexey Shashurin, Michael Keidar, Anthony D. Sandler
Journal: Cancer Research (2013)

Abstract Neuroblastoma is a common extra-cranial solid tumor in children. There are several clinical categories of this disease, ranging from curable to very poor prognosis in which this cancer is treated with multi-modal therapy. We have tested a novel ablative technology, using non-thermal helium generated plasma jets, as a means to selective targeting of neuroblastoma cells. Plasma consists of partially ionized molecules, free radicals and other species. We have investigated the molecular mechanisms involved in non-thermal plasma mediated tumor cell death, as well as the differences in response between tumor and normal cells. Treatment with non-thermal plasma induced apoptosis in cancer cells, while normal cells appear to be less sensitive to the toxic effects. Levels of reactive oxygen species (ROS) such as superoxide anion and hydrogen peroxide are elevated after plasma treatment, suggesting that this may contribute to cell death. Scavengers of ROS were able to abrogate apoptosis in plasma-treated cells. Plasma therapy of tumor cells may be a novel approach to delivery of high levels of ROS, offering the ability to directly target and selectively destroy neoplastic tissue. Methods enhancing the ROS effect and/or technical delivery of the free radicals uniformly to tumor cells within a mass will be needed before this technology could be translated to ablating solid tumors in vivo. Citation Format: Priya Srinivasan, Jason A. Snyder, Alexey Shashurin, Michael Keidar, Anthony D. Sandler. Development of a non-thermal plasma model for neuroblastoma treatment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2771. doi:10.1158/1538-7445.AM2013-2771 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Abstract 5444: Role of CRD-BP in the pathogenesis of human basal cell carcinoma.
Authors: Felicite Kamdem Noubissi, Tae Won Kim, Tisha Kawahara, B. Jack Longley, Eric Berg, Mohammad Athar, Vladimir S. Spiegelman
Journal: Cancer Research (2013)

Abstract Although the number of new cases of Basal Cell Carcinoma (BCC) has increased rapidly each year in the last few decades, the molecular basis of its pathogenesis is not completely understood. Activation of Hedgehog (Hh) signaling pathway was shown to be a key factor driving the development of BCC. The Wnt/β-catenin signaling pathway was also shown to be activated in BCCs and to perhaps modulate the activity of Hh pathway. We previously identified a novel mechanism by which Wnt signaling regulates the transcriptional outcome of Hh signaling pathway. We demonstrated that CRD-BP, a direct target of the Wnt/β-catenin signaling, induces the expression and transcriptional activity of the Hh transcriptional activator GLI1. We hypothesized that Wnt-induced and CRD-BP-dependent regulation of GLI1 expression and activities is important to the development of BCC. In this study, the role of CRD-BP in the development of human BCC will be discussed. Citation Format: Felicite Kamdem Noubissi, Tae Won Kim, Tisha Kawahara, B. Jack Longley, Eric Berg, Mohammad Athar, Vladimir S. Spiegelman. Role of CRD-BP in the pathogenesis of human basal cell carcinoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5444. doi:10.1158/1538-7445.AM2013-5444
Treatment of Systemic Mast-Cell Disease with Cladribine
Authors: Ayalew Tefferi, Chin-Yang Li, Joseph H. Butterfield, H. Clark Hoagland
Journal: New England Journal of Medicine (2001)

To the Editor: Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers.1 Because mast cells are derived from hematopoietic stem cells,2 we evaluated the therapeutic activity of cladribine in a patient with interferon alfa–resistant systemic mast-cell disease. A 57-year-old man was given a diagnosis of systemic mast-cell disease in 1975. At that time, he presented with back pain due to multiple compression fractures of the vertebrae and urticaria pigmentosa. After treatment with spinal irradiation, the course of the patient's illness was indolent, although he continued to have skin lesions. In 1994, he had an episode of . . .
Panel Endorses Behavioral Therapy for Cancer Pain
Authors: P. Eastman
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Panel Endorses Behavioral Therapy for Cancer Pain Get access Peggy Eastman Peggy Eastman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 22, 15 November 1995, Pages 1666–1667, https://doi.org/10.1093/jnci/87.22.1666 Published: 15 November 1995
INCREMENTAL VALUE OF RIGHT VENTRICULAR ENDOMYOCARDIAL BIOPSY TO THE PHENOTYPING OF PHOSPHOLAMBAN P.ARG14DEL MUTATION-RELATED CARDIOMYOPATHY
Authors: Wouter P. te Rijdt, Paul A. van der Zwaag, Rudolf de Boer, Maarten Van Den Berg, J. Peter van Tintelen, Albert J.H. Suurmeijer
Journal: Journal of the American College of Cardiology (2015)
793 KUPFFER CELL DERIVED INTERLEUKIN (IL)-18 INDUCES HEPATIC INFLAMMATION BY PROMOTING LYMPHOCYTE SUBSETS RECRUITMENT ON HEPATIC ENDOTHELIAL CELLS
Authors: E. Liaskou, D.R. Withers, E.H. Humphreys, J.C. Shaw, L. Tuohey, D.H. Adams, Y.H. Oo
Journal: Journal of Hepatology (2012)
P04.22 * OLIGOASTROCYTOMA DOES NOT EXIST: A MOLECULAR GENETIC REAPPRAISAL ON SINGLE-CELL LEVEL
Authors: F. Sahm, D. Reuss, C. Koelsche, J. Schittenhelm, S. Heim, C. Herold-Mende, W. Paulus, A. von Deimling
Journal: Neuro-Oncology (2014)

Astrocytoma and oligodendroglioma are histologically and genetically well-defined entities. The majority of astrocytomas harbor concurrent TP53 and ATRX mutations while most oligodendrogliomas carry the 1p/19q co-deletion. Both entities share high frequencies of IDH mutations. In contrast, oligoastrocytomas (OA) appear less clearly defined and, therefore, there is an ongoing debate whether these tumors indeed constitute an entity or whether they represent a mixed bag containing both, astrocytomas and oligodendrogliomas. We investigated 43 OAs diagnosed in different institutions employing histology, immunohistochemistry and in-situ hybridization addressing surrogates for the molecular genetic markers IDH1R132H mutation, TP53 mutation, ATRX mutation, and 1p/19q co-deletion. In all but one OA the combination of nuclear p53 accumulation and loss of ATRX expression was mutually exclusive of 1p/19q loss. In 31/43 OA only the alterations typical for oligodendroglioma were observed while in 11/43 OA only indicators for mutations associated with astrocytomas were detected. A single case exhibited both, nuclear expression of p53, loss of ATRX expression, IDH1 mutation and 1p/19q loss in all tumor cells. However, this was the only patient undergoing radiotherapy prior to surgery, possibly resulting in acquisition of this uncommon combination. In 30/31 OA with oligodendroglioma typical alterations the portions corresponding to a morphologically astrocytic part were identified to be reactive (i.e. no mutant IDH protein, no p53, ATRX, or 1p/19q aberrations). The remaining case with oligodendroglioma-typical aberrations presented with identical alterations also in the morphologically astrocytic portions. In all 11 OA with astrocytoma-typical alterations the oligodendroglial differentiated areas were neoplastic but harboured identical aberrations as the astrocytic portions. Thus, in this molecular genetic analysis in-situ, none of the 43 diffuse gliomas previously diagnosed as OA revealed separate co-existing cell populations with astrocytoma- and oligodendroglioma-characteristics in the same tumor, despite intra-tumoral heterogeneity in morphology. These data provide strong evidence against the existence of an independent OA entity.
Abstract 3947: Hypoxic regulation of RIO kinase 3 promotes cell migration and invasion
Authors: Dean C. Singleton, Pegah Rouhi, Yihai Cao, Adrian L. Harris
Journal: Cancer Research (2012)

Abstract RIO kinase 3 (RIOK3) is an atypical serine/threonine protein kinase that is located on a focal amplification at 18q11 observed in several cancer subtypes. Dysregulated expression of RIOK3 has been implicated in migration and invasion of pancreatic cancer cells (Kimmelman et al., 2008). We identified increased RIOK3 expression in microarray analysis of MCF7 cells exposed to severe hypoxia (&amp;lt;0.01% O2) for 24 h. Given the importance of intratumoural hypoxia in promoting cell invasion and metastasis we hypothesised that RIOK3 may contribute to the enhanced migratory phenotype observed in hypoxia. The expression of RIOK3 mRNA was increased 3-9 fold in a panel of cell lines (MCF7, MDA-MB-231, HCT 116 and U-87 MG) following exposure to 0.1% O2 for 48 h. Likewise, RIOK3 protein levels were also increased in each of the cell lines after 24-48 h at 0.1% O2. Knockdown of either HIF-1α or HIF-2α using siRNA reduced the hypoxic up-regulation of RIOK3, suggesting that RIOK3 transcription is mediated by both HIF-1 and HIF-2. To investigate RIOK3 expression in tissue, immunohistochemistry was carried out on tumour spheroids. A modest increase in RIOK3 expression was observed in the hypoxic, pimonidazole-binding area adjacent to the necrotic core. Noticeably, the RIOK3 stain in these hypoxic regions relocalised to the cell membrane, in contrast to the predominantly cytoplasmic localisation in cells located in the oxygenated rim of the spheroid suggesting a role in cytoskeletal organisation. Depletion of RIOK3 using siRNA (siRIOK3) caused MDA-MB-231 cells to become long and spindle-shaped with a reduction of the number of lamellipodia, confirming a role for RIOK3 in cytoskeletal organisation. In the scratch wound assay, siRIOK3 caused a modest reduction in MDA-MB-231 migration in normoxic conditions but strongly inhibited migration in hypoxia. Likewise, MDA-MB-231 invasion through Matrigel was increased approximately 7-fold by 1% O2 and this effect was completely abolished in siRIOK3 cells. To investigate the role of RIOK3 in invasion and metastasis in vivo we utilised a zebrafish tumour model (Rouhi et al., 2010). Following implantation into the perivitelline cavity of developing embryos, metastasis of siRIOK3 cells was significantly reduced compared with control siRNA-transfected MDA-MB-231 cells resulting in 49% less disseminated cells and foci (P &amp;lt; 0.01). In addition to genomic amplification, we have demonstrated that HIF-dependent increased expression of RIOK3 occurs and contributes to cell migration and invasion in hypoxia. References: Kimmelman et al., (2008) PNAS 105(49): 19372-7 Rouhi et al., (2010) Nat Protoc. 5(12): 1911-8 Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3947. doi:1538-7445.AM2012-3947
Case 36-2012
Authors: Robert L. Sheridan, Pamela W. Schaefer, Michael Whalen, Shawn Fagan, Frederick J. Stoddard, Jeffrey C. Schneider, Brock McConkey, Leopoldo C. Cancio
Journal: New England Journal of Medicine (2012)

Pr e sen tat ion of C a seA 16-year-old girl was admitted to this hospital because of trauma and extensive burns sustained in a motor-vehicle accident.The patient had been well until the day of admission when, while driving alone and restrained with a seat belt, her vehicle collided at high speed with a tree and burst into flames.She reportedly had blunt head trauma and was trapped in the burning vehicle with windows closed for approximately 10 minutes, until extricated by passersby who shattered a window.She reportedly was initially awake and in severe pain.Emergency medical service responders sedated and intubated her at the scene because of extensive burns to the face and concern for airway patency.She was immobilized with a cervical collar and a backboard and was transported by medical helicopter to this hospital.The patient had a history of hypothyroidism, for which she took levothyroxine daily.She had no known allergies.She was a high-school student, lived with her parents and a sibling, and was a highly competitive athlete.On examination in the emergency department, the patient was unconscious, sedated, and paralyzed, and the trachea was intubated.The temperature was 35.6°C, the blood pressure 156/101 mm Hg, the pulse 108 beats per minute, and the oxygen saturation 100% while high-flow oxygen was being delivered.The pupils were 2 mm in diameter and minimally reactive bilaterally.There were intermittent, slight spontaneous movements of both arms and the left leg.There were burns on the face, vibrissae, eyebrows, eyelashes, hair, and scalp.Full-thickness burns involved approximately 70% of the skin surface, including most of the torso and distal limbs, which were tense on examination.The legs had sustained distal soft-tissue avulsion with extensive soft-tissue loss.Spared areas included the left upper chest and the posterior-medial portion of the left leg and thigh.There were large, stellate lacerations on the anterior right knee.Breath sounds were normal, and the chest was stable.The abdomen was soft and not distended.The pelvis was stable.There were palpable pulses in the left wrist and leg.No pulses were identified in the right wrist, right leg, or feet by palpation or by noninvasive Doppler studies.A subclavian venous catheter, nasogastric tube, and bladder catheter were placed; the latter drained bright-red urine.
PTU-063 A Prospective Audit Of The Use Of Tacrolimus In Patients With Refractory Subacute Ulcerative Colitis In A District General Hospital
Authors: AS Dhillon, AW Harris
Journal: Gut (2014)

<h3>Introduction</h3> Tacrolimus appears to be effective short-term treatment for patients with refractory ulcerative colitis (UC)<sup>1</sup> and is recommended by NICE<sup>2</sup> in suitable patients. We report our experience in a district general hospital out-patient setting of tacrolimus in patients with steroid refractory subacute UC whom either failed, or were intolerant to thiopurines and as an alternate to surgery. In England, Wales and Northern Ireland infliximab may no longer be used to treat patients with sub-acute UC.<sup>3</sup> <h3>Methods</h3> A prospective quality and safely assurance audit was undertaken of all patients with UC treated with tacrolimus from January 2010 until January 2014. Patients not responding to or intolerant of conventional therapy met with the consultant gastroenterologist (AWH). They were offered treatment with tacrolimus, provided with written drug information or referral for surgical management. All agreed to start treatment with tacrolimus (Prograf) 0.1 mg/kg/day in 2 divided doses and were monitored according to local protocol with FBC, UandEs and serum trough levels at weeks 2, 4 and 3 monthly thereafter. The dose of tacrolimus was titrated aiming for serum trough levels between 5–20 ng/mL. Clinical response was assessed by AWH in clinic. <h3>Results</h3> Seventeen patients (8 female; mean age 38 [range 19–86]) were treated with tacrolimus. Eleven patients (65%) had a clinical response (median treatment duration 12 [range 2–192] weeks). Four of these (45%) patients developed intolerance to tacrolimus (renal impairment n = 2; tremor n = 1; paraesthesia n = 1) and stopped treatment. Seven patients continued on tacrolimus with clinical response and without side effects. Of the 10 patients whom either failed to respond or were intolerant of tacrolimus, 7 underwent colectomy. Of the remaining 3 patients, 1 declined surgery and 2 patients have responded to treatment with methotrexate. <h3>Conclusion</h3> Our experience supports the use of tacrolimus in patients with subacute UC refractory to conventional treatments as an alternative to elective surgery as infliximab is no longer recommended in these circumstances.<sup>3</sup> However only 7 of 17 (41%) patients had a clinical response and tolerated tacrolimus. Close monitoring of renal function and serum trough levels is required. The long-term efficacy and safety of tacrolimus remains unclear. <h3>References</h3> Baumgart DC, MacDonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. <i>Cochrane Database of Systematic Reviews</i> 2008, Issue 3. Art. No.: CD007216. DOI: 10.1002/14651858. CD007216 National Institute for Health and Care Excellence Ulcerative colitis: management in adults, children and young people CG 2013;166 National Institute for Health and Care Excellence Infliximab for subacute manifestations of ulcerative colitis TA 2008;140 <h3>Disclosure of Interest</h3> None Declared.
AB1155-HPR The Relationship of Goal Management with Fatigue over One Year in Patients with Polyarthritis
Authors: C. Bode, E. Taal, R.Y. Arends, M. Van de Laar
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Many patients with polyarthritis experience severe fatigue. How to cope with severe fatigue in polyarthritis is unclear. For related symptoms as pain, depressive feelings and feelings of anxiety some studies have pointed to the beneficial effects of goal management. <h3>Objectives</h3> Aim of this study was to describe the relationship of four goal management strategies (goal maintenance, goal adjustment, goal disengagement, goal re-engagement) and fatigue (severity, impact and coping) in a longitudinal perspective. <h3>Methods</h3> 331 patients (61% women, mean age=61 years, mean disease duration=14 years) participated in a questionnaire study with measurements at baseline, after six and twelve months. Goal management was measured by TenFlex and GAS, fatigue was assessed by 3 visual analogue scales, asking for the severity and impact of fatigue and coping with fatigue. <h3>Results</h3> The studied aspects of fatigue and the use of goal management strategies were stable over the course of one year. In regression analyses higher use of goal adjustment was significantly related to less severe fatigue, less impact of fatigue and better coping with fatigue. Unexpectedly, higher goal reengagement was related to more severe fatigue. Goal maintenance and goal disengagement did not contribute to the explanation of fatigue. <h3>Conclusions</h3> The results indicated stability of goal management and levels of fatigue over one year. For patients with elevated levels of fatigue it might be beneficial to change the way they deal with fatigue by adjusting personal goals. The role of goal re-engagement in relation to fatigue should be further explored since previous studies with related symptoms showed opposite relationships. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4657
THU0245 Association of Autoantibodies with Disease Activity in Rheumatoid Arthritis
Authors: D. Aletaha, F. Alasti, J.S. Smolen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity. <h3>Methods</h3> We used baseline data from four recent randomized controlled clinical trials of RA (one in early RA patients on rituximab, RTX; three on golimumab, GOL, in early and established populations). The effects of RF and ACPA on individual and composite measures of disease activity were investigated by using stratified analysis and a matched analysis. <h3>Results</h3> A total of 2118 patients were analysed in the four studies. In both, the RTX and the pooled GOL cohorts, RF+ patients, regardless of ACPA status, had the highest levels of baseline disease activity, while ACPA+ patients had similar or lower disease activity than ACPA- patients, regardless of RF status (See Figure, using Simplified Disease Acitivty Index, SDAI). When patients from the RTX trial were matched for the levels of ACPA, as well as for age, gender, and duration of RA (n=29), SDAI levels were 49.3±14.5 in the presence of high positive RF, and 42.3±12.7 in patients who were RF negative; this was the opposite for ACPA in patients matched for RF levels and the same covariates: high positive ACPA: 45.8±14.8; ACPA negative: 53.1±16.5 (p=0.025). These trends were supported in the respective analyses in the pooled GOL trials (RF high vs. neg.: SDAI of 36.8 vs. 33.1; ACPA high vs. neg.: 37.0 vs. 39.5), although the difference did not reach statistical significance. Figure. Simplified Disease Activity Index at baseline of the rituximab trial (left panel) or the pooled golimumab trials (right panel) by groups of RF/ACPA status. <h3>Conclusions</h3> The data suggest that the presence of RF rather than ACPA is related to higher disease activity. When matched for RF levels, ACPA had little influence on disease activity, if at all, with the tendency towards lower disease activity for ACPA+ patients. <h3>Acknowledgements</h3> We thank Roche and Janssen for providing anonymised patient level data from their clinical trials. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4396
PWE-189 Achieving high quality colonoscopy: using graphical representation to measure performance and reset standards: Abstract PWE-189 Figure 1
Authors: P T Rajasekhar, M D Rutter, M G Bramble, D W Wilson, J E East, J R Greenaway, B P Saunders, T J Lee, R Barton, P Hungin, C J Rees
Journal: Gut (2012)

<h3>Introduction</h3> The aim of colonoscopy is to examine the colon completely and meticulously looking for malignant and pre-malignant lesions (adenomas). The measure for completeness is the caecal intubation rate (CIR) and for thoroughness the adenoma detection rate (ADR). National Standards (NS) are ≥90% and ≥10% respectively.<sup>1</sup> Variability in CIR, ADR and thusly quality, have been shown but comparison between individuals and units is difficult.<sup>2 3</sup> We aimed to use graphical representation to assess colonoscopy performance in the North East of England. <h3>Methods</h3> Data on colonoscopy performance and sedation use were collected over 3 months from 12 units. Colonoscopies performed by screening colonoscopists were included in the global CIR only. Funnel plots with upper and lower 95% confidence limits (CL) for CIR and ADR were created using the binomial probability distributions for inferences about a single proportion. <h3>Results</h3> CIR was 92.5% (n=5720) and ADR 15.9% (n=4748). All units and 128 (99.2%) colonoscopists were above the lower limit for CIR. All units achieved the ADR standard with 10 above the upper limit. Ninety-nine (76.7%) colonoscopists were above 10%, 16 (12.4%) above the upper limit and 7 (5.4%) below the lower limit (Abstract PWE-189 figure 1). Median medication doses were: 2.2 mg midazolam, 29.4 mg pethidine, and 83.3 mg fentanyl. 15.1% of colonoscopies were unsedated. Complications were bleeding (0.10%) and perforation (0.02%). There was 1 death possibly related to bowel preparation. <h3>Conclusion</h3> Results indicate colonoscopies are performed safely and to a high standard. Funnel plots can highlight variability and areas for improvement. Analyses of ADR presented graphically around the global mean suggest that the NS should be reset at 15%. <h3>Competing interests</h3> None declared. <h3>References</h3> 1. <b>The Joint Advisory Group for Gastrointestinal Endoscopy</b>. Guidance for colonoscopy certification and continued practice. Dr Colin Rees and Dr John Painter. 2006. http://www.thejag.org.uk 2. <b>Bowles CJ</b>, Leicester R, Romaya C. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for the national colorectal cancer screening tomorrow? <i>Gut</i> 2004;<b>53</b>:277–83. 3. <b>van Rijn JC</b>, Reitsma JB, Stoker J, <i>et al.</i> Polyp miss rate determined by tandem colonoscopy: a systematic review. <i>Am J Gastroenterol</i> 2006;<b>101</b>:343–50.